Over the past year there were no insider purchases at Spero Therapeutics, Inc.. Two insiders sold roughly $552,000 instead.
That's worth context: executives sell for plenty of routine reasons, from scheduled trading plans to tax bills. Buying is the rarer, more telling signal.
60 investment managers listed SPRO in their latest 13F filings (Q2 2026); more funds bought than sold. No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| May 6, 2026 | Rajavelu Esther | Officer | Sell | 25,240 | $2.51 | $63K | SEC |
| Feb 9, 2026 | Rajavelu Esther | Officer | Sell | 37,101 | $2.36 | $88K | SEC |
| Feb 9, 2026 | Rajavelu Esther | Officer | Sell | 50,816 | $2.36 | $120K | SEC |
| Feb 9, 2026 | Keutzer Timothy | COO | Sell | 18,652 | $2.36 | $44K | SEC |
| Feb 5, 2026 | Keutzer Timothy | COO | Sell | 3,471 | $2.24 | $8K | SEC |
| Feb 5, 2026 | Keutzer Timothy | COO | Sell | 24,224 | $2.14 | $52K | SEC |
| Feb 5, 2026 | Keutzer Timothy | COO | Sell | 18,891 | $2.20 | $42K | SEC |
| Feb 4, 2026 | Rajavelu Esther | Officer | Sell | 18,442 | $2.20 | $41K | SEC |
| Nov 12, 2025 | Rajavelu Esther | Officer | Sell | 40,270 | $2.37 | $95K | SEC |
| Sep 3, 2025 | Mahadevia Ankit | Director | Sell | 6,572 | $1.97 | $13K | SEC |
| Sep 3, 2025 | Keutzer Timothy | COO | Sell | 1,695 | $1.97 | $3K | SEC |
| Feb 5, 2025 | Keutzer Timothy | COO | Sell | 3,974 | $0.78 | $3K | SEC |
| Feb 5, 2025 | Rajavelu Esther | CFO | Sell | 20,689 | $0.78 | $16K | SEC |
| Feb 5, 2025 | Shukla Sath | CEO | Sell | 6,139 | $0.78 | $5K | SEC |
| Feb 5, 2025 | Mahadevia Ankit | Director | Sell | 13,959 | $0.78 | $11K | SEC |
In the last 12 months Spero Therapeutics, Inc. insiders made open-market purchases worth about $0 and sales worth about $552,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in SPRO was filed on 2026-05-06.
60 investment managers reported holding SPRO in SEC Form 13F filings for Q2 2026.
No congressional trades in SPRO were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).